Exploring Bias and Limited Data in the Pfizer Clinical Trial

The chapter focuses on the potential dangers of starting a new phase of the COVID vaccine development without finishing the previous one and the limited data available. Specifically, it examines the Pfizer clinical trial, noting biases in the trial design and the safety and effectiveness claims based on limited follow-up. The question of intentional biases or innocent scientific errors is also posed.